S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
NYSE:VOR

Vor Biopharma (VOR) News Today

$2.12
0.00 (0.00%)
(As of 09/29/2023 ET)
Compare
Today's Range
$2.08
$2.24
50-Day Range
$2.10
$3.17
52-Week Range
$2.03
$7.57
Volume
110,989 shs
Average Volume
76,146 shs
Market Capitalization
$143.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.19
SourceHeadline
MarketBeat logoVor Biopharma Inc. (NYSE:VOR) Receives Average Rating of "Buy" from Analysts
americanbankingnews.com - September 30 at 2:22 AM
marketbeat.com logoBaker BROS. Advisors LP Trims Stock Position in Vor Biopharma Inc. (NYSE:VOR)
marketbeat.com - September 12 at 5:41 AM
markets.businessinsider.com logoJonesTrading Initiates a Buy Rating on Prime Medicine, Inc. (PRME)
markets.businessinsider.com - September 5 at 8:38 PM
marketbeat.com logoVor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by Brokerages
marketbeat.com - September 5 at 2:16 AM
fool.com logoVor Biopharma (NASDAQ: VOR)
fool.com - August 16 at 9:02 PM
msn.com logoJMP Securities Reiterates Vor Biopharma (VOR) Market Outperform Recommendation
msn.com - August 14 at 4:20 PM
markets.businessinsider.com logoThe Latest Analyst Ratings for Vor Biopharma
markets.businessinsider.com - August 14 at 4:20 PM
gurufocus.com logoRA Capital Management, L.P. Increases Stake in Vor Biopharma Inc.
gurufocus.com - August 12 at 5:04 AM
markets.businessinsider.com logoBarclays Keeps Their Buy Rating on Vor Biopharma (VOR)
markets.businessinsider.com - August 12 at 12:41 AM
markets.businessinsider.com logoH.C. Wainwright Reaffirms Their Buy Rating on Vor Biopharma (VOR)
markets.businessinsider.com - August 11 at 7:39 PM
msn.com logoWedbush Maintains Vor Biopharma (VOR) Outperform Recommendation
msn.com - August 11 at 7:39 PM
marketbeat.com logoVor Biopharma (NYSE:VOR) Price Target Lowered to $15.00 at Stifel Nicolaus
marketbeat.com - August 11 at 1:45 PM
marketbeat.com logoVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Buy" by Analysts
marketbeat.com - August 11 at 10:49 AM
finance.yahoo.com logoVor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
finance.yahoo.com - August 11 at 3:14 AM
technews.tmcnet.com logoSolu Therapeutics Debuts with $31 Million in Seed Funding to Unlock Antibody-Intractable Cell Surface Targets
technews.tmcnet.com - August 1 at 8:37 PM
finanznachrichten.de logoVeeva Systems: Veeva Pulse Uncovers Field Medical Engagement Drives 1.5x Increase in Treatment Adoption
finanznachrichten.de - July 26 at 4:42 PM
de.finance.yahoo.com logoVeeva Pulse zeigt, dass Interaktionen mit dem medizinischen Außendienst die Therapieakzeptanz um das 1,5-fache steigern
de.finance.yahoo.com - July 26 at 4:42 PM
markets.businessinsider.com logoRobert W. Baird Sticks to Its Buy Rating for Bluebird Bio (BLUE)
markets.businessinsider.com - June 22 at 7:23 AM
markets.businessinsider.com logoRobert W. Baird Keeps Their Buy Rating on Vor Biopharma (VOR)
markets.businessinsider.com - June 22 at 7:23 AM
markets.businessinsider.com logoPOINT Biopharma Global (PNT) Gets a Buy from JonesTrading
markets.businessinsider.com - June 21 at 9:20 AM
marketbeat.com logoVor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of "Buy" by Brokerages
marketbeat.com - June 19 at 4:34 AM
markets.businessinsider.com logoWhat 11 Analyst Ratings Have To Say About Vor Biopharma
markets.businessinsider.com - June 12 at 6:59 PM
markets.businessinsider.com logoVor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients
markets.businessinsider.com - June 9 at 2:50 PM
finanznachrichten.de logoVor Biopharma: Successful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio's Platform
finanznachrichten.de - June 9 at 9:50 AM
finance.yahoo.com logoSuccessful Primary Engraftment of Trem-cel in First Five AML Patients Demonstrates Promise of Vor Bio’s Platform
finance.yahoo.com - June 9 at 9:50 AM
finance.yahoo.com logoVor Bio to Participate in the Goldman Sachs Healthcare Conference
finance.yahoo.com - June 5 at 10:50 AM
uk.finance.yahoo.com logoVOR - Vor Biopharma Inc.
uk.finance.yahoo.com - May 25 at 8:48 AM
msn.com logoJonesTrading Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation
msn.com - May 16 at 8:24 PM
msn.com logoOppenheimer Reiterates Vor Biopharma (VOR) Outperform Recommendation
msn.com - May 16 at 3:23 PM
msn.com logoHC Wainwright & Co. Reiterates Vor Biopharma (VOR) Buy Recommendation
msn.com - May 16 at 3:23 PM
markets.businessinsider.com logoVor Biopharma (VOR) Gets a Buy from H.C. Wainwright
markets.businessinsider.com - May 16 at 10:18 AM
markets.businessinsider.com logoOppenheimer Sticks to Their Buy Rating for Vor Biopharma (VOR)
markets.businessinsider.com - May 15 at 7:24 PM
msn.com logo8 Analysts Have This to Say About Vor Biopharma
msn.com - May 15 at 7:24 PM
marketbeat.com logoWedbush Weighs in on Vor Biopharma Inc.'s FY2027 Earnings (NYSE:VOR)
marketbeat.com - May 15 at 4:38 AM
markets.businessinsider.com logoWedbush Reaffirms Their Buy Rating on Vor Biopharma (VOR)
markets.businessinsider.com - May 12 at 5:56 PM
msn.com logoWedbush Reiterates Vor Biopharma (VOR) Outperform Recommendation
msn.com - May 12 at 12:55 PM
markets.businessinsider.com logoJMP Securities Remains a Buy on Vor Biopharma (VOR)
markets.businessinsider.com - May 12 at 2:54 AM
de.investing.com logoVor Biopharma: EPS übertrifft Schätzungen um 0,11$ - Umsatz wie erwartet
de.investing.com - May 11 at 9:53 PM
msn.com logoVor Biopharma GAAP EPS of -$0.43 misses by $0.05
msn.com - May 11 at 9:53 PM
msn.com logoVor Biopharma: Q1 Earnings Insights
msn.com - May 11 at 9:53 PM
finance.yahoo.com logoVor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
finance.yahoo.com - May 11 at 4:53 PM
marketbeat.com logoVor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of "Buy" by Analysts
marketbeat.com - April 30 at 4:14 AM
marketbeat.com logoVor Biopharma Inc. (NYSE:VOR) Given Average Rating of "Moderate Buy" by Brokerages
marketbeat.com - April 5 at 4:33 AM
seekingalpha.com logoVor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells
seekingalpha.com - March 29 at 7:11 PM
finance.yahoo.com logoHow Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
finance.yahoo.com - March 28 at 12:21 PM
marketbeat.com logoWedbush Weighs in on Vor Biopharma Inc.'s Q1 2024 Earnings (NYSE:VOR)
marketbeat.com - March 27 at 2:38 AM
marketbeat.com logoBarclays Cuts Vor Biopharma (NYSE:VOR) Price Target to $10.00
marketbeat.com - March 26 at 7:28 AM
uk.finance.yahoo.com logoVor Biopharma Inc. (VOR) stock historical prices & data – Yahoo Finance
uk.finance.yahoo.com - March 25 at 11:38 PM
markets.businessinsider.com logoWhere Vor Biopharma Stands With Analysts
markets.businessinsider.com - March 24 at 2:59 PM
msn.com logoTruist Securities Maintains Buy Rating for Vor Biopharma: Here's What You Need To Know
msn.com - March 24 at 2:59 PM
Get Vor Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.



VOR Media Mentions By Week

VOR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VOR
News Sentiment

0.00

0.68

Average
Medical
News Sentiment

VOR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VOR Articles
This Week

1

1

VOR Articles
Average Week

Get Vor Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NYSE:VOR) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -